There are 1,205 papers on testosterone in aging research: 270 trials and 395 observational studies in people, 233 in animals, 13 in cells, 276 reviews. The newest story, Nov 9, 2026: “DNA variants relevant to menopause show varied health links”.
Testosterone is associated with mortality, bone density and lean mass in human cohorts of men. A longitudinal study links increasing age with declining levels in healthy men. Human trials report increases with exercise, whereas a trial in women with polycystic ovary syndrome reports a decrease.
523 findings in 417 papers from 1978 to 2026, 64 of them since April 2026
“Changes in 6MWT distance were significantly associated with changes in testosterone, free testosterone, dihydrotestosterone, and haemoglobin concentrations”
↑upin humans15↔no changein humans3↑upin human cells1↑upin mice1+1+192% above basal levels
20 studies
Dehydroepiandrosterone increases testosterone in humans.
“The change from baseline to 12 weeks in estrone and testosterone (total and free) concentrations also significantly differed from PM for both doses of DHEA.”
Dehydroepiandrosterone increases testosterone in humans.
“Significant increases in mean DHEA, DHEA sulfate (DHEA-S), testosterone, and androstenedione levels were noted with DHEA alone or combined DHEA/CEE treatments when compared with placebo.”
Testosterone increases testosterone in humans (post-menopausal women with HSDD on estrogen-containing HRT) (unadjusted median Cmax 6.25 nmol/L, Cavg 4.51 nmol/L).
“The unadjusted median Cmax testosterone concentration was 6.25 nmol/L (range 1.3-26.1), and Cavg was 4.51 nmol/L (range 0.93-20.21).”
Human trialpost-menopausal women with HSDD on estrogen-containing HRT16.2 mg/g gel via pumpserum20.25 mgfemalesn = 24
Journal of cardiovascular pharmacology and therapeutics·
Testosterone increases testosterone in humans (addition of transdermal testosterone to EPT).
“Significant differences were found in serum total testosterone levels among women with POI receiving T treatment, compared with placebo after three months and at 12 months (P < 0.001 for both groups at each time interval respectively).”
Human trialaddition of transdermal testosterone to EPTone yearfemalesn = 128
The aging male : the official journal of the International Society for the Study of the Aging Male·
Testosterone increases testosterone in humans (elderly men with relative testosterone insufficiency) (10.0 +/- 1.9 nmol/l in Group 1, 6.6 +/- 1.6 nmol/l in Group 2).
“Serum testosterone increased by a mean of 10.0 +/- 1.9, 6.6 +/- 1.6, 0.52 +/- 0.6, and 0.5 +/- 0.6 nmol/l in Groups 1, 2, 3, and 4 respectively.”
Human trialelderly men with relative testosterone insufficiency12 weeksmalesn = 70
Exercise decreases testosterone in humans (polycystic ovary syndrome).
“exercise significantly reduced total testosterone (TT), free testosterone, fasting insulin, and homeostatic model assessment of insulin resistance (HOMA-IR)”
“Specific training modalities may attenuate or reverse parts of this decline, increasing serum concentrations of hormones like testosterone (ZOUHAL et al., 2022) and growth hormone”
Resistance training increases testosterone in both healthy and sarcopenic men.
“Follistatin and testosterone increased in the healthy group; in contrast, only testosterone increased in the sarcopenic group after training (P < 0.05).”
Human trialin both healthy and sarcopenic men8 weeksmales
The journal of obstetrics and gynaecology research·
Ashwagandha increases testosterone in humans (+14.7%).
“The 2 × 2 crossover, two-sample t-test confirmed significantly higher levels of DHEA-S (T37 = 2.97, p =.005) and testosterone (T36 = 2.74, p =.010) during ashwagandha intake, compared to placebo intake (18.0% and 14.7%, respectively).”
Ashwagandha increases testosterone in humans (undergoing weight training) (Placebo: 18.00 ng/dL vs. Ashwagandha: 96.19 ng/dL).
“The increase in testosterone level was significantly greater with ashwagandha supplementation than with the placebo (Placebo: 18.00 ng/dL, 95 % CI, -15.83, 51.82 vs. Ashwagandha: 96.19 ng/dL, 95 % CI, 54.86, 137.53; p = 0.004).”
Human trialundergoing weight training8 weeksmalesn = 57
Journal of the International Society of Sports Nutrition·
Ashwagandha increases testosterone in humans (engaged in resistance training) (96.2 ng/dL (95% CI 54.7, 137.5) vs 18.0 ng/dL (95% CI -15.8, 51.8), p = 0.004).
“significantly greater increase in testosterone level (Placebo: 18.0 ng/dL, 95% CI, -15.8, 51.8 vs. Ashwagandha: 96.2 ng/dL, 95% CI, 54.7, 137.5; p = 0.004)”
Human trialengaged in resistance trainingroot extract300 mg twice daily8 weeksmalesn = 57
Aerobic exercise decreases testosterone in patients with polycystic ovary syndrome (g = -0.5120, 95% CI [-0.8230 to -0.2010]).
“Subgroup analysis revealed that the "aerobic exercise" group was statistically significant (k = 14, g = -0.5120, 95% CI [-0.8230 to -0.2010], P = 0.0027).”
Human trialin patients with polycystic ovary syndromeserumfemales
Sildenafil increases testosterone in rats (acute in vivo PDE5 inhibition).
“Acute in vivo PDE5 inhibition overaccumulated cGMP and stimulated testosterone but reduced ATP production in Leydig cells from adult, middle-aged, and old rats”
Animalsacute in vivo PDE5 inhibitionLeydig cellsacute
The Journal of clinical endocrinology and metabolism·
Resveratrol increases testosterone in Cd-exposed mice.
“mice treated with resveratrol (50 mg/kg), a specific SIRT1 activator, mitigated Leydig cell senescence and reversed Cd-reduced testosterone levels in mouse testes.”
Quercetin decreases testosterone in humans (overweight or obese women with polycystic ovary syndrome) (0.72 ± 0.15 vs. 0.76 ± 0.12 ng/ml, p = 0.001).
“testosterone (0.72 ± 0.15 vs. 0.76 ± 0.12 ng/ml, p = 0.001) and LH (8.05 ± 2.88 vs. 8.77 ± 1.99 mIU/ml, p = 0.035) concentrations were significantly lower in quercetin”
Human trialoverweight or obese women with polycystic ovary syndromecirculatory1,000 mg/day12 weeksfemalesn = 78
Quercetin decreases testosterone in humans (polycystic ovary syndrome) (0.71 ng/dl in quercetin vs. 0.77 ng/dl in placebo).
“while it reduced the level of testosterone (0.71 ng/dl in quercetin vs. 0.77 ng/dl in placebo; p<0.001) and LH (8.42 IU/l in quercetin vs. 8.68 IU/l in placebo; p=0.009).”
Human trialpolycystic ovary syndrome1 g daily12 weeksfemalesn = 84
Time-restricted feeding showed no clear effect on testosterone in humans (Premenopausal and postmenopausal females with obesity; before-and-after comparison).
“Circulating levels of testosterone, androstenedione, and sex hormone binding globulin (SHBG) did not change in either group”
Human trialPremenopausal and postmenopausal females with obesity; before-and-after comparison4- to 6-hour eating window8 weeksfemales
Time-restricted feeding showed no clear effect on testosterone in rats (alone or in combination).
“neither IF nor PT, alone or in combination, resulted in improvements in testosterone levels or AR expression in the gastrocnemius muscle. with testosterone levels remained unchanged.”
Animalsalone or in combinationgastrocnemius muscle8 weeksmales
Limosilactobacillus reuteri showed no clear effect on testosterone in humans (well within the reference intervals given for the age group).
“In our case all study participants are well within the reference intervals given for the age group for the investigated parameters e.g., testosterone, SHGB, LH and FSH and thereby not considered deficient in these parameters.”
Human trialwell within the reference intervals given for the age group12 weeksmalesn = 49
Lacticaseibacillus paracasei increases testosterone in humans.
“Testosterone levels were also significantly higher in the HT-PS23 group than in the placebo group after 6 and 12 weeks of supplementation (p = 0.035 each).”
Testosterone showed no clear effect on cognitive function in humans (community-dwelling postmenopausal women; majority of included observational studies).
“The majority of studies reported no association between total or free testosterone and cognitive performance.”
Reviewcommunity-dwelling postmenopausal women; majority of included observational studiesfemales
Testosterone showed no clear effect on cardiovascular mortality in humans (Per 5 nmol/L increase in endogenous testosterone) (HR 0.95, 95% CI 0.83 to 1.08 per 5 nmol/L increase).
“Analyses of published estimates did not demonstrate associations of endogenous testosterone with CVD deaths or with all-cause mortality.”
ReviewPer 5 nmol/L increase in endogenous testosteroneAt least 5 years of follow-upmales
Testosterone was not clearly linked with mortality in humans (Adjusted for risk factors; per 1 SD increase in testosterone) (Adjusted HR 0.90, 95% CI 0.79–1.04 per 1 SD increase).
“T was not associated with mortality (adjusted HR = 0·90, 95% CI 0·79-1·04; P = 0·164 for every increase in 1 SD of T)”
HumansAdjusted for risk factors; per 1 SD increase in testosteroneMean follow-up of 14.9 yearsmalesn = 1,804
Testosterone showed no clear effect on mortality in humans (Per 5 nmol/L increase in endogenous testosterone) (HR 0.96, 95% CI 0.89 to 1.03 per 5 nmol/L increase).
“no significant effect of a 5 nmol/L increase in testosterone on the risk of all-cause mortality (HR=0.96, 95% CI 0.89 to 1.03)”
ReviewPer 5 nmol/L increase in endogenous testosteroneAt least 5 years of follow-upmalesn = 20,180
Testosterone is linked with sarcopenia in humans (association with outdoor light exposure) (6.82% for TSO; 5.14% for OLI).
“A considerable part of these relationships was explained by vitamin D (9.49% for TSO; 8.44% for OLI) and testosterone (6.82% for TSO; 5.14% for OLI).”
Testosterone is linked with sarcopenia in humans (sedentary time and sarcopenia risk) (8.56% mediation).
“Furthermore, SII, 25(OH)D, and testosterone showed a significant mediation in the association between sedentary time and sarcopenia risk, with a mediation effect of 3.39 %, 10.3 %, and 8.56 %, respectively.”
Testosterone was not clearly linked with frailty in humans (prostate cancer patients under androgen deprivation therapy) (p = 0.60).
“There were significant relationships between frailty syndrome and the systemic concentration of androstenedione (p = 0.01), but not the concentration of testosterone (p = 0.60) or DHEA (p = 0.42).”
Humansprostate cancer patients under androgen deprivation therapyplasmamales
Testosterone is linked with stroke in humans (association between sex (women versus men) and risk of stroke) (indirect effect 2.48 (95% CI, 1.27-6.17)).
“indirect effects were 2.48 (95% CI, 1.27-6.17) and 2.90 (95% CI, 1.67-6.35) for total testosterone and dihydrotestosterone, respectively.”
Humansassociation between sex (women versus men) and risk of strokemedian follow-up of 8.6 yearsn = 1,970
Testosterone was not clearly linked with measured GFR decline in humans (multivariable-adjusted linear mixed model) (-0.02 [-0.04 to 0.01] ml/min per 1.73 m2 per year per nmol/L).
“Neither TT, FT, nor SHBG were associated with mGFR decline in the multivariable-adjusted linear mixed model analyses”
Humansmultivariable-adjusted linear mixed modelmedian follow-up of 10.9 yearsmalesn = 800
Testosterone showed no clear effect on bone mineral density in humans (between baseline T < 264 ng/dl and ≥ 264 ng/dl groups during testosterone therapy).
“No significant differences in BMD and bone turnover markers were observed.”
Human trialbetween baseline T < 264 ng/dl and ≥ 264 ng/dl groups during testosterone therapy18 monthsmales
Testosterone decreases fasting blood glucose in humans (testosterone therapy in men with baseline T ≥ 264 ng/dl vs < 264 ng/dl) (-4.2 ± 31.9 vs. 13.0 ± 57.3%).
“fasting glucose at 18 months (-4.2 ± 31.9 vs. 13.0 ± 57.3%; p = 0.040)”
Human trialtestosterone therapy in men with baseline T ≥ 264 ng/dl vs < 264 ng/dl18 monthsmales
Testosterone decreases glycated hemoglobin in humans (testosterone therapy in men with baseline T ≥ 264 ng/dl vs < 264 ng/dl) (-3.1 ± 9.2 vs. 3.2 ± 13.9%).
“Men with T ≥ 264 ng/dl showed significant decreases in HbA1c at 12 months (-3.1 ± 9.2 vs. 3.2 ± 13.9%; p = 0.005)”
Human trialtestosterone therapy in men with baseline T ≥ 264 ng/dl vs < 264 ng/dl12 monthsmales
Testosterone increases total fat-free mass in humans (testosterone therapy in men with baseline T < 264 ng/dl vs ≥ 264 ng/dl) (4.2 ± 4.1 vs. 2.7 ± 3.8%).
“Men with T < 264 ng/dl showed greater increases in total fat-free mass (FFM) at 18 months compared to those with T ≥ 264 ng/dl (4.2 ± 4.1 vs. 2.7 ± 3.8%; p = 0.047)”
Human trialtestosterone therapy in men with baseline T < 264 ng/dl vs ≥ 264 ng/dl18 monthsmales
Age is linked with lower testosterone in humans (0.56 nmol/L vs 0.42 nmol/L, p = 0.001).
“Median testosterone concentrations declined between the ages of 40-44 and 55-59 years (median (interdecile range) 0.56 (0.29-1.01) nmol/L vs 0.42 (0.21-0.79) nmol/L, p = 0.001 adjusted for BMI and smoking)”
Age decreases testosterone in rats (aging rats (24 months) compared with youth controls).
“Compared with the youth controls, telomerase activity in the testis, testosterone levels, expression of AR, and expression of antiapoptosis factor Bcl-2 protein and mRNA were significantly decreased”
Animalsaging rats (24 months) compared with youth controlstestismalesn = 8
Late-onset hypogonadism decreases testosterone in humans (aging).
“The core pathophysiological link of LOH lies in the progressive decline of testosterone levels caused by the reduction in the number and functional decline of Leydig cells (LCs).”
Late-onset hypogonadism decreases testosterone in humans.
“Aging men with late-onset hypogonadism (LOH) experience physiologic, psychiatric, and sexual symptoms related to a decline in the serum concentration of testosterone with age.”
Obesity decreases testosterone in humans (metabolic disorders).
“Metabolic disorders such as obesity and hyperlipidemia accelerate Leydig cell aging, reduce testosterone levels, and contribute to the development of LOH.”
Polycystic ovary syndrome is linked with higher testosterone in humans (late reproductive years) (p < 0.001, p = 0.001 and p = 0.032).
“Testosterone, free androgen index, and fasting insulin were higher in PCOS patients than controls (p < 0.001, p = 0.001 and p = 0.032, respectively).”
Polycystic ovary syndrome is linked with higher testosterone in humans after 13 years of follow-up.
“PCOS patients still had higher levels of total testosterone, free androgen index (FAI) and dehydroepiandrosterone sulfate (DHEAS) levels compared to controls.”
Testosterone is associated with cognitive function in humans (mild Alzheimer's disease) (r = 0.83, p < 0.001).
“Changes in salivary T levels were positively (r = 0.83; p < 0.001) and C levels were negatively (r = -0.86; p < 0.001) correlated in the PR, MT and MT + PR groups with changes in MMSE in AD patients.”
Human trialmild Alzheimer's disease4 monthsmalesn = 26
Testosterone is associated with cognitive function in humans (adjusted odds ratio: 4.72, 95% confidence interval: 1.06-21.00).
“men with low testosterone concentrations had a significantly greater risk of low cognitive performance than those with high testosterone concentrations (adjusted odds ratio: 4.72, 95% confidence interval: 1.06-21.00)”
Testosterone is associated with cognitive function in adjusted group (OR = 0.51; 95%CI = 0.27-0.95).
“higher concentrations of total testosterone were associated with better performance on CERAD test (OR = 0.51; 95%CI = 0.27-0.95) and DSST (OR = 0.54; 95%CI = 0.30-0.99) in adjusted group”
Testosterone is linked with a lower risk of mortality in humans (HR 0.892, 95% CI 0.830-0.959).
“Higher testosterone levels were associated with lower risks of all-cause mortality (hazard ratio (HR) 0.892, 95% confidence interval (CI) 0.830-0.959; P = 0.002)”
Testosterone is associated with mortality in humans.
“Analysis of all-cause mortality-which included deaths from any known disease-also revealed greater general risk for those with lower testosterone levels.”
Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]·
Sarcopenia is associated with testosterone in patients with sarcopenia compared with non-sarcopenia (369 vs. 497.5 ng/ml, p = 0.03).
“The non-sarcopenia group had significantly larger PV (40 vs. 20 ml, p < 0.01) and higher testosterone levels (497.5 vs. 369 ng/ml, p = 0.03) compared with the sarcopenia group”
Humansin patients with sarcopenia compared with non-sarcopeniamalesn = 59
Testosterone is associated with sarcopenia in humans (OR 0.95, 95% CI 0.89-1.00).
“Continuous FT levels was positively associated with the prevalence of sarcopenia in men (odds ratio [OR]=0.95; 95% confidence interval [CI]=0.89-1.00)”
The Journal of clinical endocrinology and metabolism·
Testosterone is associated with cardiovascular disease in humans.
“Decreased testosterone level is associated with a range of systemic diseases and comorbidities, including cardiovascular disease, cognitive decline, depression, osteoporosis, frailty, increased body fat, and metabolic syndrome.”
Testosterone is associated with cardiovascular disease in humans (Klinefelter syndrome and older men).
“low endogenous serum T appears to be associated with higher risk of cardiovascular disease and overall mortality in certain populations such as Klinefelter syndrome and older men”
Testosterone is associated with cardiovascular disease in humans.
“studies reporting a significant association of high levels of testosterone with a reduced risk of CVD events in original prospective studies and meta-analyses of cross-sectional and prospective studies seems to be more consistent”
Testosterone predicts osteoporosis in humans (p < 0.05).
“Older age, lower BMI, elevated ALP, lower testosterone, and elevated lipoprotein(a) levels were identified as independent predictors for osteoporosis (p < 0.05 for all).”
Clinical and Experimental Obstetrics & Gynecology·
Testosterone is associated with osteoporosis in humans (p-value < 0.001).
“There was a significant correlation between serum testosterone levels and the severity of osteoporosis according to Singh index grade among older men (p-value < 0.001).”
Testosterone is linked with a lower risk of type 2 diabetes in humans (OR 0.92, 95% CI 0.87–0.97, p = 0.001).
“An independent inverse relationship between serum testosterone concentration and 5-year incident T2D was observed (OR = 0.92, 95% CI = [0.87, 0.97], p = 0.001).”
Smoking is associated with testosterone in humans.
“Total testosterone levels were modestly correlated with directly measured free testosterone, estradiol, estrone, DHT, and SHBG, and weakly negatively associated with body mass index and smoking.”
The journals of gerontology. Series A, Biological sciences and medical sciences·
Testosterone is associated with muscle strength in humans.
“Significant positive correlation was observed between changes in serum T with muscle mass, strength, and hemoglobin but not with PSA across the three time-points.”
Physical activity is associated with testosterone in humans (r = 0.40, p<0.01).
“In addition, the percentage changes in serum testosterone levels were significantly correlated with that in the total number of steps taken per day (r = 0.40, p<0.01).”
Metformin is associated with testosterone in humans (PCOS; before-and-after comparison without an untreated comparator) (0.81 ± 0.07 to 0.73 ± 0.08 ng/mL).
“Testosterone declined significantly from 0.81 ± 0.07 to 0.73 ± 0.08 ng/mL (p < 0.001)”
Human trialPCOS; before-and-after comparison without an untreated comparatormaximum of 2.55–3.0 g/day6 monthsfemalesn = 120
Contains public sector information licensed under the Open Government Licence v3.0.
How this record changed
Summary rewritten as its findings changed.
As it read before
Human observational studies associate testosterone with mortality, bone mineral density, and lean mass in men; lower levels are associated with sarcopenia. Human trials report increases with exercise but decreases with exercise in women with polycystic ovary syndrome. In male rats, resveratrol and melatonin do not alter age-related testosterone decline.
A longitudinal study reports declining testosterone with age in healthy older men, while human observational studies associate lower levels with sarcopenia and cognitive impairment in men. A human preprint links testosterone to higher mortality risk given men's health and inflammation; a mouse study reports no effect of testosterone on frailty in males.
Summary rewritten as its findings changed.
As it read before
Human studies associate higher testosterone with lower mortality, less cognitive impairment and greater grip strength in men, while a study in women finds no mortality association. Lower levels are associated with sarcopenia in men; higher levels correlate with poorer verbal fluency and visuoconstruction in women.
Summary rewritten as its findings changed.
As it read before
A human preprint links testosterone to declining cerebellar volumes in females; another links it to an ADHD brain functional profile. A review preprint describes testosterone reductions with weight loss in humans.
An observational genomic analysis linked 25 of 31 menopause-relevant DNA variants to at least one trait, with associations spanning up to 16 traits per variant.An observational genomic analysis linked 25 of 31 menopause-relevant DNA variants to at least one trait, with associations spanning up to 16 traits per variant.
In an animal experiment, adding Synage to a brain region increased testosterone, sperm counts and forward sperm movement in 12-month-old mice.In an animal experiment, adding Synage to a brain region increased testosterone, sperm counts and forward sperm movement in 12-month-old mice.